BeOne Medicines Ltd. (BeOne Medicines) has activated a fresh offering cycle for its Sixth Amended and Restated 2018 Employee Share Purchase Plan (2018 ESPP), in line with Hong Kong Listing Rules 17.06A–C.

The latest offering period began on 1 September 2026 and will run through 26 February 2027, following an enrolment window from 17 to 31 August 2026. A total of 5,316 eligible employees—those on the payroll from the start of both the enrolment and offering periods, excluding anyone who would hold 5 % or more of the Company’s voting power post-purchase—have enrolled. Participants may opt out at any time before the period closes.

Key commercial parameters include:

• Purchase discount: 15 % to market price, with employees buying shares (or ADSs) at 85 % of the lower of the Nasdaq closing price on the first (1 September 2026) or last (26 February 2027) trading day of the period. • Initial reference price: USD 358.65 per American Depositary Share (ADS), equivalent to approximately HKD 216.29 per underlying Share at an exchange rate of USD 1 = HKD 7.84. • Payroll deduction limits: 1 %–10 % of eligible earnings, capped at USD 25,000 per employee per calendar year. • Remaining pool: 4.82 million Shares were available for grant under the scheme mandate as of 1 September 2026, prior to accounting for purchases that will be executed at the end of this new cycle.

The 2018 ESPP, overseen by the Board’s compensation committee, carries no performance conditions and does not incorporate a claw-back mechanism, consistent with prevailing market practice. No company-funded financial assistance is provided to participants.

Management reiterates that the plan is intended to strengthen employee engagement and align workforce interests with those of shareholders. All disclosures comply with applicable Hong Kong regulatory requirements, and additional details—including the final number of Shares purchased in the March–August 2026 offering—will be disclosed once available.